CFTR and cystic fibrosis: Acknowledging its anti-inflammatory effects and CFTR-modulatory potential, TMA received an Orphan Drug Designation for CF treatment by the European Medicines Agency (EMA) in 2013 (EU/3/13/1137) [116].